We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometrial Priming for Embryo Transfer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01430650
First Posted: September 8, 2011
Last Update Posted: September 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Miguel Angel Checa, Parc de Salut Mar
  Purpose

The aim of this trial is compare two different endometrial priming protocols

  • women that receive oral estrogens
  • women that receive transdermal estrogens

Condition Intervention Phase
Sterility Drug: Oral strogen Drug: Transdermal strogen Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.

Further study details as provided by Miguel Angel Checa, Parc de Salut Mar:

Primary Outcome Measures:
  • Difference between day means in endometrial priming to achieve 7 mm. [ Time Frame: 11-16 days ]

Secondary Outcome Measures:
  • Biochemical Pregnancy rate [ Time Frame: 26-30 days ]
    To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embryonary transference and multiply by 100.

  • The patient's adherence to the recommended treatment. [ Time Frame: 1-16 days ]

Enrollment: 140
Study Start Date: July 2010
Study Completion Date: July 2015
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral strogen Drug: Oral strogen
2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
Experimental: Transdermal strogen Drug: Transdermal strogen
One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women between 18-50 years old with desire of children and needs of embryo transfer.
  • Plasma prolactin less than 30.
  • Uterine cavity that allow pregnancy, body mass index between 20-30.
  • And signed consent inform.

Exclusion Criteria:

  • History of estrogen dependent cancer, unknown origin vaginal bleeding.
  • Ovarian cyst.
  • Contraindications to be pregnant.
  • Estrogen allergy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01430650


Locations
Spain
Hospital del Mar
Barcelona, Spain, 08003
Sponsors and Collaborators
Parc de Salut Mar
  More Information

Responsible Party: Miguel Angel Checa, MD, Parc de Salut Mar
ClinicalTrials.gov Identifier: NCT01430650     History of Changes
Other Study ID Numbers: UREP-PREPENDO-2010
First Submitted: June 20, 2011
First Posted: September 8, 2011
Last Update Posted: September 20, 2017
Last Verified: September 2017

Keywords provided by Miguel Angel Checa, Parc de Salut Mar:
Oral estrogens
transdermal estrogens
endometrial priming

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female
Estrogens
Permixon
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Androgen Antagonists
Hormone Antagonists
Estrogen Antagonists


To Top